Virtual Network's Login.
REMINDER:
Abstract Submission and Registration
are open!
DON'T DELAY:
About the Conference:
The successful biannual ESH Conferences on Acute Myeloid Leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation. Novel technological, molecular and immunologic approaches are rapidly creating novel insights into the biology and therapeutic perspectives of AML.
The cutting-edge program of the conference will deal with the molecular and functional features of leukemic stem cells and their interaction with the microenvironment, the role of somatic and germ-line mutations and epigenetic alterations in the biology of AML, the genomics of leukemogenesis, advances in molecular diagnostics and developmental therapeutics with a focus on molecular and immunotherapeutic targeted therapeutics.
Special attention will be given to the utility and promise of novel therapeutic agents.
This meeting will be of interest to:
• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
• Junior scientists and clinicians (MD, PhD)
• PhD candidates and clinical residents still in-training
CONFERENCE MAIN SCIENTIFIC TOPICS:
• Preleukemic hematopoiesis and clonal diversity
• Preleukemic conditions and predisposition
• Epigenetics
• MDS / Secondary leukemia
• Immune targeting
• Therapeutic targeting
LEARNING OBJECTIVES
1. Understand the pathobiology of leukemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways.
2. Acquire insight into the possible mechanisms of inherited and preleukemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.
3. Understand the characterization of a leukemia stem cell and its relationship to disease development and phenotype.
4. Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia and its clinical impact.
5. Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions.
6. Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, drug resistance mechanisms, the current developmental status of various targeted drugs and novel antibody-based and cell-transfer based immunotherapeutic approaches and their promises for future clinical application.
